{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:38:40Z","timestamp":1790501920382,"version":"4.1.0"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000078","name":"Division of Materials Research","doi-asserted-by":"publisher","award":["DMR-1308276"],"award-info":[{"award-number":["DMR-1308276"]}],"id":[{"id":"10.13039\/100000078","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000078","name":"Division of Materials Research","doi-asserted-by":"publisher","award":["DMR-1309218"],"award-info":[{"award-number":["DMR-1309218"]}],"id":[{"id":"10.13039\/100000078","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000151","name":"Division of Industrial Innovation and Partnerships","doi-asserted-by":"publisher","award":["IIP-1312157"],"award-info":[{"award-number":["IIP-1312157"]}],"id":[{"id":"10.13039\/100000151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005296","name":"American Association of Pharmaceutical Scientists","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011501","name":"Institute for Critical Technologies and Applied Science, Virginia Tech","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100011501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Macromolecules Innovation Institute, Virginia Polytechnic Institute and State University","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug therapy has been instrumental in prolonging the lives of patients infected by human immunodeficiency virus (HIV). In order to combat development of resistance, therapies involving three or more drugs in combination are recommended by the World Health Organization (WHO) to suppress HIV and prevent development of acquired immune deficiency syndrome (AIDS). It is desirable for multidrug combinations to be coformulated into single dosage forms where possible, to promote patient convenience and adherence to dosage regimens, for which amorphous solid dispersion (ASD) is particularly well-suited. We investigated multidrug ASDs of three model anti-HIV drugs, ritonavir (Rit), etravirine (Etra), and efavirenz (Efa), in cellulosic polymer matrices. We hypothesized that the presence of multiple drugs would reduce crystallization tendency, thereby providing stable, supersaturating formulations for bioavailability enhancement. We explored new ASD polymers including cellulose acetate suberate (DSSub 0.9, CASub) and cellulose acetate adipate propionate (DSAd 0.9, CAAdP), and control commercial cellulosic polymers including 6-carboxycellulose acetate butyrate (CCAB) and carboxymethyl cellulose acetate butyrate (CMCAB). We succeeded in preparing three-drug ASDs containing very high drug loadings (45% drug total; 15% of each drug); each polymer tested was effective at stabilizing the amorphous drugs in the solid phase, as demonstrated by XRD, SEM, and DSC studies. In pH 6.8 dissolution studies ASDs released each anti-HIV drug over 8 h, affording supersaturated solutions of each drug, but unexpectedly failing in some cases to reach maximum possible supersaturation. In a second set of dissolution studies (pH 6.8), the cause of the observed solution concentration limitations was investigated by studying release from single- and two-drug ASDs. Concentrations of Rit, Etra, and Efa achieved from three-drug ASDs were higher than those achieved from crystalline drugs. Surprisingly, however, there was a decrease in the achieved drug concentrations of both Rit and Efa when they dissolved together, while Etra solution concentration was enhanced by the presence of Rit and Efa in the ASD. We demonstrate that these effects have to do primarily with solution phase interactions between the anti-HIV drugs, rather than from the drugs influencing each other\u2019s release rate, and we suggest that such observations may indicate an important, previously inadequately recognized, and general phenomenon for ASDs containing multiple hydrophobic drugs.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.7b00203","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T16:48:58Z","timestamp":1504630138000},"page":"3617-3627","source":"Crossref","is-referenced-by-count":32,"title":["Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature\nand Mechanisms of Impacts of Drugs on Each Other\u2019s Solution\nConcentrations"],"prefix":"10.1021","volume":"14","author":[{"given":"Hale C\u0327ig\u0306dem","family":"Arca","sequence":"first","affiliation":[{"name":"Virginia Tech , , , ,","place":["Blacksburg, Virginia, United States, 24061"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I.","family":"Mosquera-Giraldo","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga","family":"Dahal","sequence":"additional","affiliation":[{"name":"Virginia Tech , , , ,","place":["Blacksburg, Virginia, United States, 24061"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-6021","authenticated-orcid":true,"given":"Lynne S.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-9477","authenticated-orcid":true,"given":"Kevin J.","family":"Edgar","sequence":"additional","affiliation":[{"name":"Virginia Tech , , , ,","place":["Blacksburg, Virginia, United States, 24061"]},{"name":"Virginia Tech , , , ,","place":["Blacksburg, Virginia, United States, 24061"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"2026090221462830300_cit1","volume-title":"Global\nAIDS Update 2016","year":"2016"},{"key":"2026090221462830300_cit2","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1126\/science.1079864","article-title":"Prospects\nfor the Future","volume":"298","author":"Gallo","year":"2002","journal-title":"Science"},{"key":"2026090221462830300_cit3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-Six\nYears of Anti-HIV Drug Discovery: Where\nDo We Stand and Where Do We Go?","volume":"53","author":"Mehellou","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090221462830300_cit4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm0703-839","article-title":"HIV and\nAIDS: 20 Years of Science","volume":"9","author":"Fauci","year":"2003","journal-title":"Nat. Med."},{"key":"2026090221462830300_cit5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV Drug Resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N. Engl.\nJ. Med."},{"key":"2026090221462830300_cit6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/095632029800900301","article-title":"Anti-Human Immunodeficiency Virus\nDrug Combination Strategies","volume":"9","author":"Vandamme","year":"1998","journal-title":"Antiviral Chem.\nChemother."},{"key":"2026090221462830300_cit7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with Indinavir, Zidovudine,\nand Lamivudine in Adults with Human Immunodeficiency Virus Infection\nand Prior Antiretroviral Therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J.\nMed."},{"key":"2026090221462830300_cit8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A Controlled Trial\nof Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency\nVirus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or\nLess","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"2026090221462830300_cit9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical\nPharmacokinetics and Pharmacodynamics of Etravirine","volume":"48","author":"Scholler-Gyure","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"2026090221462830300_cit10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV Drugs: 25 Compounds Approved within 25 Years after the Discovery\nof HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2026090221462830300_cit11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","article-title":"Self-Reported\nSymptoms and Medication Side Effects Influence Adherence to Highly\nActive Antiretroviral Therapy in Persons with HIV Infection","volume":"28","author":"Ammassari","year":"2001","journal-title":"JAIDS, J. Acquired Immune Defic. Syndr."},{"key":"2026090221462830300_cit12","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.drudis.2014.05.012","article-title":"An analysis of FDA-approved\ndrugs for infectious disease:\nHIV\/AIDS drugs","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discovery Today"},{"key":"2026090221462830300_cit13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid Dispersions\nas Strategy to\nImprove Oral Bioavailability of Poor Water Soluble Drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discovery Today"},{"key":"2026090221462830300_cit14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.addr.2009.11.019","article-title":"Pure Drug and Polymer Based Nanotechnologies\nfor the Improved Solubility,\nStability, Bioavailability and Targeting of Anti-HIV Drugs","volume":"62","author":"Sharma","year":"2010","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026090221462830300_cit15","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1021\/cg4007058","article-title":"New Solid Forms\nof the Anti-HIV Drug\nEtravirine: Salts, Cocrystals, and Solubility","volume":"13","author":"Rajput","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"2026090221462830300_cit16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2009.05.007","article-title":"Drug Delivery Systems in HIV Pharmacotherapy:\nWhat Has Been Done and the Challenges Standing Ahead","volume":"138","author":"Sosnik","year":"2009","journal-title":"J. Controlled Release"},{"key":"2026090221462830300_cit17","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1021\/mp300104s","article-title":"A Win\u2013Win\nSolution in Oral Delivery of Lipophilic Drugs: Supersaturation via\nAmorphous Solid Dispersions Increases Apparent Solubility without\nSacrifice of Intestinal Membrane Permeability","volume":"9","author":"Miller","year":"2012","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous Drug Systems: Enhanced Physical Stability and Dissolution\nRate of Indomethacin and Naproxen","volume":"8","author":"Lobmann","year":"2011","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.carbpol.2012.11.049","article-title":"Synthesis and Structure-Property\nEvaluation of Cellulose\n\u03c9-Carboxyesters for Amorphous Solid Dispersions","volume":"100","author":"Liu","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"2026090221462830300_cit20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1021\/cg301447d","article-title":"Maintaining\nSupersaturation in Aqueous\nDrug Solutions: Impact of Different Polymers on Induction Times","volume":"13","author":"Ilevbare","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"2026090221462830300_cit21","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1021\/mp400441d","article-title":"Interplay\nof Degradation, Dissolution and Stabilization of Clarithromycin and\nIts Amorphous Solid Dispersions","volume":"10","author":"Pereira","year":"2013","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit22","unstructured":"Buchanan, C. M.; Buchanan, N. L.; Carty, S. N.; Kuo, C. M.; Lambert, J. L.; Posey-Dowty, J. D.; Watterson, T. L.; Wood, M. D.; Malcolm, M. O.; Lindblad, M. S.\n          Cellulose Interpolymers\nand Methods of Oxidation; US8816066 B2, 2014."},{"key":"2026090221462830300_cit23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/mp5006245","article-title":"Impact of Surfactants\non the Crystallization of Aqueous Suspensions of Celecoxib Amorphous\nSolid Dispersion Spray Dried Particles","volume":"12","author":"Chen","year":"2015","journal-title":"Mol.\nPharmaceutics"},{"key":"2026090221462830300_cit24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejps.2005.04.003","article-title":"Enhanced Oral\nPaclitaxel Absorption with Vitamin E-TPGS:\nEffect on Solubility and Permeability in Vitro, in Situ and in Vivo","volume":"25","author":"Varma","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090221462830300_cit25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2005.11.005","article-title":"Influence\nof Vitamin\nE TPGS Poly(ethylene Glycol) Chain Length on Apical. Efflux Transporters\nin Caco-2 Cell Monolayers","volume":"111","author":"Collnot","year":"2006","journal-title":"J. Controlled Release"},{"key":"2026090221462830300_cit26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1021\/mp060121r","article-title":"Mechanism\nof Inhibition of P-Glycoprotein Mediated Efflux by Vitamin E TPGS:\nInfluence on ATPase Activity and Membrane Fluidity","volume":"4","author":"Collnot","year":"2007","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1021\/bm101448f","article-title":"Synthesis of Cellulose Adipate Derivatives","volume":"12","author":"Kar","year":"2011","journal-title":"Biomacromolecules"},{"key":"2026090221462830300_cit28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.carbpol.2012.11.049","article-title":"Synthesis and Structure\u2013property Evaluation\nof Cellulose \u03c9-Carboxyesters for Amorphous Solid Dispersions","volume":"100","author":"Liu","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"2026090221462830300_cit29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jps.22242","article-title":"Physicochemical Properties of the\nAmorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation\nProbability of Success for Solid Dispersions: Etravirine","volume":"100","author":"Weuts","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jps.21811","article-title":"An Investigation\ninto the Crystallisation Behaviour of an Amorphous Cryomilled Pharmaceutical\nMaterial above and below the Glass Transition Temperature","volume":"99","author":"Qi","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit31","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1002\/jps.23125","article-title":"Amorphous-State\nCharacterization of Efavirenz--Polymer Hot-Melt Extrusion Systems\nfor Dissolution Enhancement","volume":"101","author":"Sathigari","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jps.20633","article-title":"A Calorimetric\nInvestigation of Thermodynamic and Molecular Mobility Contributions\nto the Physical Stability of Two Pharmaceutical Glasses","volume":"96","author":"Zhou","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit33","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1021\/mp400029v","article-title":"Impact of Polymers on Crystal Growth\nRate of Structurally Diverse Compounds from Aqueous Solution","volume":"10","author":"Ilevbare","year":"2013","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejps.2008.06.010","article-title":"Free Flowing Solid Dispersions of the Anti-HIV Drug\nUC 781 with Poloxamer 407 and a Maximum Amount of TPGS 1000: Investigating\nthe Relationship between Physicochemical Characteristics and Dissolution\nBehaviour","volume":"35","author":"Goddeeris","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090221462830300_cit35","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1002\/jps.23125","article-title":"Amorphous-State\nCharacterization of Efavirenz\u2500polymer Hot-Melt Extrusion Systems\nfor Dissolution Enhancement","volume":"101","author":"Sathigari","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit36","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The Use of Amorphous Solid Dispersions: A Formulation\nStrategy to Overcome Poor Solubility and Dissolution Rate","volume":"9","author":"Van den Mooter","year":"2012","journal-title":"Drug Discovery Today: Technol."},{"key":"2026090221462830300_cit37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1021\/mp100377m","article-title":"Excipient-Mediated\nSupersaturation Stabilization in\nHuman Intestinal Fluids","volume":"8","author":"Bevernage","year":"2011","journal-title":"Mol. Pharmaceutics"},{"key":"2026090221462830300_cit38","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1021\/cg300325p","article-title":"Understanding Polymer Properties\nImportant for Crystal Growth Inhibition \u2013 Impact of Chemically\nDiverse Polymers on Solution Crystal Growth of Ritonavir","volume":"12","author":"Ilevbare","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"2026090221462830300_cit39","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1039\/c2ce25515d","article-title":"Inhibition of Solution Crystal Growth\nof Ritonavir by Cellulose Polymers \u2013 Factors Influencing Polymer\nEffectiveness","volume":"14","author":"Ilevbare","year":"2012","journal-title":"CrystEngComm"},{"key":"2026090221462830300_cit40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.carbpol.2016.09.067","article-title":"Novel Cellulose-Based\nAmorphous Solid Dispersions Enhance Quercetin Solution Concentrations\nIn Vitro","volume":"157","author":"Gilley","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"2026090221462830300_cit41","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/jps.24528","article-title":"Thermodynamics of\nHighly Supersaturated Aqueous Solutions\nof Poorly Water-Soluble Drugs\u2500Impact of a Second Drug on the\nSolution Phase Behavior and Implications for Combination Products","volume":"104","author":"Trasi","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"2026090221462830300_cit42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2016.03.028","article-title":"Compromised in Vitro\nDissolution and Membrane Transport of Multidrug Amorphous Formulations","volume":"229","author":"Alhalaweh","year":"2016","journal-title":"J. Controlled Release"},{"key":"2026090221462830300_cit43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2015.10.026","article-title":"Dissolution Performance of Binary\nAmorphous Drug Combinations\n\u2500 Impact of a Second Drug on the Maximum Achievable Supersaturation","volume":"496","author":"Trasi","year":"2015","journal-title":"Int. J. Pharm."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00203","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/11\/3617\/67090880\/acs.molpharmaceut.7b00203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/11\/3617\/67090880\/acs.molpharmaceut.7b00203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:34Z","timestamp":1788400174000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/14\/11\/3617\/737809\/Multidrug-Anti-HIV-Amorphous-Solid-Dispersions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,9,5]]},"published-print":{"date-parts":[[2017,11,6]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00203","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]}}}